'indian ip and liabilities law barrier to pharma r&d investment'
.
.
in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance.
.
�this negligence must not be allowed to continue,� budkie�s letter states. �the university of california, berkeley, has clearly failed to follow federal regulations and guidelines.�
.
.
.
.